Form 4: Exelixis EVP and CFO Christopher J. Senner Reports Acquisition of 82,121 Shares of Common Stock

Christopher J. Senner, EVP and CFO of Exelixis, Inc., reports acquiring 82,121 shares of common stock through restricted stock units and holding 751,990 shares directly and 2,723 indirectly through a 401(k).

Summary

• On February 23, 2024, Christopher J. Senner, the EVP and CFO of Exelixis, Inc., acquired 82,121 shares of Exelixis common stock.
• These shares were obtained through the vesting of restricted stock units (RSUs) granted under the Exelixis, Inc. 2017 Equity Incentive Plan.
• The RSUs will vest in four equal installments, starting on May 15, 2025, and then annually on each subsequent May 15th until fully vested.
• Following this transaction, Senner directly owns 751,990 shares of Exelixis common stock, including shares issuable upon vesting of RSUs.
• Senner also indirectly owns 2,723 shares through the Exelixis, Inc. 401(k) Plan, as of February 22, 2024.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. It's a routine filing showing an executive acquiring shares, which can be interpreted as a sign of confidence, but it's not a major event.

Positives

• The acquisition of shares by a high-ranking executive like the CFO can be seen as a positive signal, indicating confidence in the company's future performance.

Future Outlook

The restricted stock units will vest in four equal installments, starting on May 15, 2025, and then annually on each subsequent May 15th until fully vested.

Industry Context

Form 4 filings are a routine part of insider trading regulations, providing transparency into the transactions of company executives and directors. This filing indicates the CFO's continued investment in the company's stock, which is common practice for executives.

Comparison to Industry Standards

• Executive compensation packages often include stock options and restricted stock units to align management's interests with those of shareholders.
• The vesting schedule of the RSUs (1/4th annually starting May 15, 2025) is a fairly standard vesting schedule.
• Comparing the total holdings of Christopher J. Senner to those of CFOs at comparable biotech companies (e.g., Gilead, Amgen, Biogen) would provide further context on the significance of his ownership stake.

Stakeholder Impact

• The acquisition of shares by the CFO could have a slightly positive impact on shareholder sentiment.

Key Dates